Kura Oncology (KURA)
(Real Time Quote from BATS)
$21.11 USD
+0.33 (1.59%)
Updated Jul 26, 2024 03:44 PM ET
After-Market: $21.08 -0.03 (-0.14%) 4:06 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Kura Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 166 | 140 | 131 | 92 | 67 |
Income After Depreciation & Amortization | -166 | -140 | -131 | -92 | -67 |
Non-Operating Income | 15 | 4 | 1 | 3 | 5 |
Interest Expense | 2 | 0 | 0 | 1 | 1 |
Pretax Income | -153 | -136 | -130 | -90 | -63 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -153 | -136 | -130 | -90 | -63 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -153 | -136 | -130 | -90 | -63 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -174 | -137 | -126 | -91 | -69 |
Depreciation & Amortization (Cash Flow) | -9 | 2 | 5 | 1 | -1 |
Income After Depreciation & Amortization | -166 | -140 | -131 | -92 | -67 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.23 | 66.99 | 66.35 | 53.08 | 41.95 |
Diluted EPS Before Non-Recurring Items | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 |
Diluted Net EPS (GAAP) | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 |
Fiscal Year end for Kura Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 54.45 | 46.76 | 42.48 | 40.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -54.45 | -46.76 | -42.48 | -40.00 |
Non-Operating Income | NA | 5.33 | 4.37 | 4.28 | 3.22 |
Interest Expense | NA | 0.40 | 0.39 | 0.40 | 0.39 |
Pretax Income | NA | -49.53 | -42.79 | -38.60 | -37.17 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -49.53 | -42.79 | -38.60 | -37.17 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -49.53 | -42.79 | -38.60 | -37.17 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 83.91 | 77.38 | 77.24 | 69.80 |
Diluted EPS Before Non-Recurring Items | NA | -0.59 | -0.55 | -0.50 | -0.53 |
Diluted Net EPS (GAAP) | NA | -0.59 | -0.55 | -0.50 | -0.53 |